Cargando…
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638077/ https://www.ncbi.nlm.nih.gov/pubmed/36899091 http://dx.doi.org/10.1038/s41391-023-00656-4 |
| _version_ | 1785146550424436736 |
|---|---|
| author | Wenzel, Mike Nocera, Luigi Collà Ruvolo, Claudia Würnschimmel, Christoph Tian, Zhe Shariat, Shahrokh F. Saad, Fred Tilki, Derya Graefen, Markus Kluth, Luis A. Briganti, Alberto Mandel, Philipp Montorsi, Francesco Chun, Felix K. H. Karakiewicz, Pierre I. |
| author_facet | Wenzel, Mike Nocera, Luigi Collà Ruvolo, Claudia Würnschimmel, Christoph Tian, Zhe Shariat, Shahrokh F. Saad, Fred Tilki, Derya Graefen, Markus Kluth, Luis A. Briganti, Alberto Mandel, Philipp Montorsi, Francesco Chun, Felix K. H. Karakiewicz, Pierre I. |
| author_sort | Wenzel, Mike |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10638077 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106380772023-11-15 Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis Wenzel, Mike Nocera, Luigi Collà Ruvolo, Claudia Würnschimmel, Christoph Tian, Zhe Shariat, Shahrokh F. Saad, Fred Tilki, Derya Graefen, Markus Kluth, Luis A. Briganti, Alberto Mandel, Philipp Montorsi, Francesco Chun, Felix K. H. Karakiewicz, Pierre I. Prostate Cancer Prostatic Dis Correction Nature Publishing Group UK 2023-03-10 2023 /pmc/articles/PMC10638077/ /pubmed/36899091 http://dx.doi.org/10.1038/s41391-023-00656-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Wenzel, Mike Nocera, Luigi Collà Ruvolo, Claudia Würnschimmel, Christoph Tian, Zhe Shariat, Shahrokh F. Saad, Fred Tilki, Derya Graefen, Markus Kluth, Luis A. Briganti, Alberto Mandel, Philipp Montorsi, Francesco Chun, Felix K. H. Karakiewicz, Pierre I. Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis |
| title | Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis |
| title_full | Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis |
| title_fullStr | Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis |
| title_full_unstemmed | Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis |
| title_short | Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis |
| title_sort | correction: overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638077/ https://www.ncbi.nlm.nih.gov/pubmed/36899091 http://dx.doi.org/10.1038/s41391-023-00656-4 |
| work_keys_str_mv | AT wenzelmike correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT noceraluigi correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT collaruvoloclaudia correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT wurnschimmelchristoph correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT tianzhe correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT shariatshahrokhf correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT saadfred correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT tilkiderya correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT graefenmarkus correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT kluthluisa correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT brigantialberto correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT mandelphilipp correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT montorsifrancesco correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT chunfelixkh correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis AT karakiewiczpierrei correctionoverallsurvivalandadverseeventsaftertreatmentwithdarolutamidevsapalutamidevsenzalutamideforhighrisknonmetastaticcastrationresistantprostatecancerasystematicreviewandnetworkmetaanalysis |